Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158211 | 0.84 | KMT2A (0.40) | CYP11B2CYP11B1MAOAKMT2AKDM4E | |
| SCHEMBL7952356 | 0.84 | KMT2A (0.40) | CYP11B2CYP11B1MAOAKMT2AKDM4E | |
| SCHEMBL7961100 | 0.82 | DPP4 (0.33) | CHRNB4CHRNA3USP30 | |
| SCHEMBL7962938 | 0.81 | CYP11B2 (0.36) | CYP11B2CYP11B1KMT2AKDM4EHSD17B10 | |
| SCHEMBL8328200 | 0.81 | CHRNB1 (0.35) | CYP11B2CYP11B1KMT2AKDM4EHSD17B10 | |
| SCHEMBL2157354 | 0.81 | MKNK1 (0.39) | CYP11B2CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7965546 | 0.81 | NR4A2 (0.40) | CYP11B2CYP11B1KMT2AKDM4EHTT | |
| SCHEMBL7964338 | 0.81 | CYP11B2 (0.35) | CYP11B2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL7964383 | 0.76 | FPR1 (0.39) | CYP11B2CYP11B1MAOAKMT2ARXFP1 | |
| SCHEMBL8322092 | 0.76 | CHRNB2 (0.41) | CYP11B2CYP11B1ALDH1A1CHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6207675-B1 | FOR PROPHYLAXIS AND THERAPY OF DISEASES IN WHICH ARE INVOLVED VIRUSES OF THE HERPES FAMILY AND/OR CYTOKINES IN PARTICULAR TUMOR NERCOSIS FACTOR-ALPHA | RHONE-POULENC RORER S.A. (FR) | 2001-03-27 | — | — | US | claimed |
| EP-0946555-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-06 | — | — | EP | claimed |
| WO-1998025925-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | claimed |
| EP-2361253-A1 | COMPOUNDS | Selcia Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20110184011-A1 | Compounds | SELCIA LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| WO-2010029364-A1 | COMPOUNDS | SELCIA LIMITED (GB) | 2010-03-18 | — | — | WO | disclosed |
| US-6207675-B1 | FOR PROPHYLAXIS AND THERAPY OF DISEASES IN WHICH ARE INVOLVED VIRUSES OF THE HERPES FAMILY AND/OR CYTOKINES IN PARTICULAR TUMOR NERCOSIS FACTOR-ALPHA | RHONE-POULENC RORER S.A. (FR) | 2001-03-27 | — | — | US | disclosed |
| EP-0946555-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998025925-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184011-A1 | Compounds | COL1A1, ALDH1A2, COL2A1 | CYP11B2 164/4885CYP11B1 117/4885MAOA 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.